Key Statistics for ZEL
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (EUR) (ttm)
|Est. EPS (EUR) (12/2013)
|Est. PEG Ratio
|Market Cap (M EUR)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|Cash Dividend (EUR)
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ZEL
- Net Income (M/EUR)
Zeltia, S.A. is a holding composed of biotechnological and chemical companies. The Company's main activity is developing marine derived anti-cancer drugs and CNS pathologies treatments. Zeltia's other activities include developing diagnosis kits and RNAi technology based therapeutical applications.
More Company Profile & Key Executives for ZEL
|Jose Maria Fernandez Sousa-FaroChairman||Pedro Francisco Fernandez PuentesVice Chairman|
|Maria Luisa De Francia CaballeroChief Financial Officer||Jose Luis Moreno Martinez-LosaDir:Capital Market|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.